Mylan (MYL) to Post FY2017 Earnings of $4.55 Per Share, Leerink Swann Forecasts
Mylan (NASDAQ:MYL) – Leerink Swann issued their FY2017 earnings per share (EPS) estimates for Mylan in a research report issued on Tuesday. Leerink Swann analyst A. Fadia anticipates that the company will post earnings of $4.55 per share for the year. Leerink Swann has a “Market Perform” rating and a $44.00 price objective on the stock. Leerink Swann also issued estimates for Mylan’s Q4 2017 earnings at $1.42 EPS, FY2018 earnings at $5.35 EPS, FY2019 earnings at $5.70 EPS, FY2020 earnings at $6.25 EPS and FY2021 earnings at $6.89 EPS.
Several other analysts have also recently issued reports on MYL. Citigroup reaffirmed a “buy” rating and issued a $58.00 price target (up from $48.00) on shares of Mylan in a report on Thursday. BMO Capital Markets reaffirmed a “buy” rating and issued a $45.00 price target on shares of Mylan in a report on Friday, September 29th. ValuEngine raised shares of Mylan from a “hold” rating to a “buy” rating in a report on Monday, October 2nd. Instinet reaffirmed a “buy” rating and issued a $37.00 price target on shares of Mylan in a report on Thursday, October 5th. Finally, Cowen reaffirmed a “market perform” rating and issued a $36.00 price target (up from $30.00) on shares of Mylan in a report on Thursday, October 5th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. Mylan presently has a consensus rating of “Buy” and a consensus target price of $43.20.
Shares of Mylan (NASDAQ:MYL) opened at $44.54 on Friday. The stock has a market cap of $23,770.00, a price-to-earnings ratio of 26.83, a P/E/G ratio of 1.44 and a beta of 1.38. The company has a quick ratio of 0.95, a current ratio of 1.46 and a debt-to-equity ratio of 1.05. Mylan has a twelve month low of $29.39 and a twelve month high of $45.87.
Mylan (NASDAQ:MYL) last posted its quarterly earnings results on Monday, November 6th. The company reported $1.10 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.20 by ($0.10). The company had revenue of $2.99 billion during the quarter, compared to analyst estimates of $3.09 billion. Mylan had a net margin of 7.28% and a return on equity of 20.63%. The company’s revenue was down 2.3% on a year-over-year basis. During the same period in the prior year, the company earned $1.38 earnings per share.
Several large investors have recently modified their holdings of MYL. Pzena Investment Management LLC grew its position in shares of Mylan by 84.1% during the third quarter. Pzena Investment Management LLC now owns 22,721,384 shares of the company’s stock worth $712,770,000 after acquiring an additional 10,381,697 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Mylan by 12.0% during the second quarter. Vanguard Group Inc. now owns 32,880,790 shares of the company’s stock worth $1,276,432,000 after acquiring an additional 3,531,974 shares during the last quarter. BlackRock Inc. grew its position in shares of Mylan by 4.5% during the second quarter. BlackRock Inc. now owns 40,574,158 shares of the company’s stock worth $1,575,089,000 after acquiring an additional 1,751,515 shares during the last quarter. Schroder Investment Management Group grew its position in shares of Mylan by 161,445.9% during the second quarter. Schroder Investment Management Group now owns 1,731,772 shares of the company’s stock worth $67,124,000 after acquiring an additional 1,730,700 shares during the last quarter. Finally, Teachers Advisors LLC grew its position in shares of Mylan by 72.2% during the second quarter. Teachers Advisors LLC now owns 3,346,814 shares of the company’s stock worth $129,923,000 after acquiring an additional 1,403,273 shares during the last quarter. 74.90% of the stock is currently owned by institutional investors.
Mylan Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with Analyst Ratings Network's FREE daily email newsletter.